Antibody-Drug Conjugates Mergers & Acquisitions

Acquire.fyi monitors the latest mergers and acquisitions. Since 2025, 1 M&A deals in the Antibody-Drug Conjugates category have pushed the total transaction value to $1.5B.

M&A Deals (2026)

0% vs 2025 year-to-date

Total Value (2026)

$1.5B

0% vs 2025 year-to-date

Median Deal Size (2026)

$1.5B

0% vs 2025 year-to-date

Megadeals: >$500M

0% vs 2025 year-to-date

M&A Deal Volume & Value

Historical performance in the Antibody-Drug Conjugates category.

Source: Acquire.fyi, Jan 1, 2025 - Jul 13, 2026.

Top Antibody-Drug Conjugates Deals (Last 12 Months)

Largest mergers and acquisitions by disclosed deal value.

Acquirer	Target	Type	Value	Headline
Novartis	Myricx Bio	Acquisition	$1.5B	Novartis Bets $1.5 Billion on Myricx ADC Payload Platform

Latest Antibody-Drug Conjugates Articles

Page 1 of latest articles and deal coverage.

Health | Jul 6, 2026

Novartis Bets $1.5 Billion on Myricx ADC Payload Platform

The deal gives Novartis a differentiated antibody drug conjugate engine as large pharma races to secure better-tolerated oncology assets before clinical validation drives prices higher.

Related M&A Categories

Life Sciences Biotechnology Pharmaceuticals Precision Medicine Drug Discovery